The short term influence of right ventricular pacing burden on echocardiographic and spiroergometric parameters in patients with preserved left ventricular ejection fraction

Akram Youssef1†, Christian Pfluecke2†, Maciej Dawid1, Karim Ibrahim1, Michael Günther2, Steffen Kolschmann2, Utz Richter2, Alexander Francke3, Carsten Wunderlich3 and Marian Christoph1*

Abstract

Background: The incidence of worsened clinical outcome due to high right ventricular (RV) pacing burden in patients with preserved left ventricular function remains controversial.

Objective: To investigate the impact of RV pacing on several echocardiographic and spiroergometric parameters.

Methods: In 60 pacemaker patients with preserved left ventricular ejection fraction (LVEF) serial echocardiographies and spiroergometries were performed over a time course of 12 months. Additionally, in 48 patients retrospective echocardiographic analyses of the LV- and RV function were carried out up to 24 months after pacemaker implantation.

Results: The patients were divided into two groups: The high RV pacing burden group (hRVP: ≥ 40%) and the low RV pacing group (lRVP < 40%) according to the definitions in previous randomized MOST and DAVID trials. After a period of 12-month pacemaker therapy no changes to left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), LVEF, E/A-ratio; E/E′-ratio and tricuspid annular plane systolic excursion (TAPSE) could be revealed, independently of the RV pacing burden. Additionally, after 24-month long term follow-up there were no differences in LVEF and TAPSE in both groups. Accordingly, no relevant changes of peak exercise capacity, ventilatory anaerobic threshold or maximal oxygen consumption could be demonstrated independently of the RV pacing.

Conclusions: In pacemaker patients with preserved LVEF the burden of RV pacing has no adverse influence on several echocardiographic and spiroergometric surrogate parameters of pacemaker-induced cardiomyopathy after a follow-up of 12 to 24 month. Despite this, screening for pacemaker induced cardiomyopathy should be performed especially in the presence of new heart failure symptoms.

Keywords: Ventricular pacing, Pacemaker, Echocardiography, Spiroergometry, Clinical outcome

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
parameter for pacemaker-induced cardiomyopathy and death from any cause as clinical outcome parameter depending on RV pacing burden in patients with preserved or mildly reduced left ventricular (LV) function could not reveal a predictive value of RV pacing burden [2]. In addition, a large registry of the Mayo Clinic could not observe any statistically significant change in mean LVEF in long-term follow-up of patients with initially preserved LVEF who underwent atrioventricular junction ablation and RV pacing [3]. However, in another large registry by Bansal et al. the incidence of pacemaker-induced cardiomyopathy was found to be 13.8% over a mean follow-up of 14.5 months [4]. The clinical relevance of the proposed pacemaker-induced cardiomyopathy was predominantly investigated in patients with reduced LVEF. These studies suggest an adverse clinical effect of RV pacing. With regard to clinical endpoints, the DAVID trial and the MOST trial revealed increased rates of death or hospitalization for heart failure and increased incidence of atrial fibrillation in patients with a cumulative RV pacing > 40% [5–7]. In this context, biventricular pacing has been controversially postulated as a preventive method. However, no benefits of such an approach could be found in the randomized prospective PREVENT-HF study which compared biventricular with RV apical pacing with regard to several echocardiographic parameters [8]. On the other hand, the advantages of biventricular pacing for LVEF could be demonstrated in the PACE trial [9]. Further, HIS bundle pacing is currently being investigated for the prevention of pacemaker-induced cardiomyopathy in various studies with different patient populations.

In the present clinical registry we evaluated the influence of RV pacing burden on several echocardiographic parameters. In addition, serial spiroergometric examinations were performed to investigate the clinically functional outcome of the pacemaker patients. The aim was to complement the existing data in order better to evaluate the need for screening for pacemaker-induced cardiomyopathy and potentially verify the indication for biventricular pacing and HIS bundle pacing in patients with preserved LV function.

**Methods**

**Study design**

The current study was a single-centre registry, divided into a retrospective and a prospective part, performed in compliance with the guidelines for good clinical practice and the Declaration of Helsinki. The study was approved by the institutional ethical review board. All data were collected, managed and analysed at the Heart Centre, University of Dresden (ethics votum University of Dresden: EK 28409202).

The primary endpoints of this study were the left ventricular end diastolic and end systolic diameter (LVEDD, LVESD), the systolic left ventricular function (LVEF), the diastolic left ventricular function (E/A-ratio, E/E'-ratio) and the systolic right ventricular function (tricuspid annular plane systolic excursion, TAPSE) in dependence of the RV apical pacing burden.

The secondary clinical endpoints were the changes in maximal oxygen consumption (VO₂max), maximal workload and ventilatory anaerobic threshold (VAT) in dependence of the RV apical pacing burden.

**Study population and protocol**

Eligible subjects were consecutive males or females > 18 years of age with an indication for permanent pacemaker therapy according to the European guidelines [10]. The main indications for pacemaker implantation were symptomatic sinus node dysfunction, paroxysmal or permanent second-degree type II or third-degree AV block including symptomatic bradyarrhythmia during persistent atrial fibrillation or unexplained syncope with bundle branch block or with positive electrophysiological study (HV-interval > 70 ms).

Consecutive patients who received a pacemaker from May 2010 to December 2011 and received all clinical routine follow-up visits in the study centre were included in the retrospective analysis.

The study centre is the University Hospital Dresden Heart Centre. At the time of the study, approximately 250 pacemakers per year were implanted by the co-authors MG and SK. Of these 250 patients, approximately 50 patients per year were completely followed up as part of the routine clinical practice at the university outpatient clinic. From these patients, those who had normal baseline LVEF and no other cardiac cause of worsening cardiac function besides pacemaker therapy were selected consecutively for the registry.

After the analysis of the 24-month follow-up data, the expansion to include the prospective part of the registry was done. Prospective inclusion in the registry was conducted from September 2014 to June 2015. The inclusion criteria were as follows: 1. Normal left ventricular ejection fraction > 55%, 2. Normal to mildly dilated left ventricular end diastolic diameter < 57 mm, 3. Normal right ventricular function TAPSE > 17 mm, 4. Exclusion of other cardiac causes of worsened LV function and spiroergometric parameters. If a patient fulfilled all inclusion criteria, primarily a retrospective evaluation of clinical routine echocardiographic parameters (LVEF and TAPSE) was conducted at the time of pacemaker implantation and after 24 months in 48 consecutive pacemaker patients. As there were no changes in this routine echocardiographic parameters...
in the retrospective analysis over 24 months, a prospective part was added to the registry in which the 6 and 12 month follow-up visits were expanded to include additional echocardiographic parameters (LVDD, LVESD, LVEF, E/A-ratio; E/E’-ratio and TAPSE) and spiroergometry (VO2max, peak exercise capacity, VAT).

The measurements of the echocardiographic and spiroergometric data during the follow-up visits were performed by independent staff who did not know that the data were registered. Additionally, the staff was not informed about the RV pacing burden of the patients.

Pacemaker implantation, programming and follow-up

The type of pacemaker to be implanted was selected by the responsible physician according to bradyarrhythmia type and the current guidelines [10]. All RV pacing leads were exclusively positioned in the RV apex. The correct positioning of leads in the right ventricular septal apex was confirmed by fluoroscopy in RAO and LAO view. The pacemakers were programmed immediately after implantation according to the pacemaker indication and guidelines. The first pacemaker follow-up was performed 4 weeks postoperatively. Further monitoring as well as recording of the RV apical pacing burden took place after 6, 12 and 24 months.

Transthoracic echocardiography

In all subjects an echocardiogram was performed to assess LVDD, LVESD, LVEF, E/A-ratio; E/E’-ratio and TAPSE at the time of enrollment, which was repeated at 6 and 12 months after pacemaker implantation. In the retrospective study group, LVEF and TAPSE were analyzed at the time of pacemaker implantation and 24 month afterwards. For the echocardiographic examinations, the iE33 xMatrix-DS ultrasound device from Philips (Koninklijke Philips N. V., Amsterdam, The Netherlands) with a 2.5 MHz transducer was used. All acquired echocardiograms were reviewed by a core laboratory at the Heart Center Dresden. The LVDD and LVESD was measured M-mode guided in the parasternal long-axis view. The LVEF was assessed using biplane Simpson’s rule with manual tracing of digital images [11]. TAPSE was determined with M-mode guiding in the apical 4-chambers view. Thereby, the maximal systolic excursion of the RV free wall at the junction with the tricuspid valve was measured [12]. The evaluation of LV diastolic function was determined, measuring the mitral inflow and DTI of the mitral lateral annulus. The E and A peaks as well as the e’ and a’ peaks were measured, followed by the calculation of the E/A-ratio and E/E’-ratio [13].

Spiroergometry

In all subjects a spiroergometry was performed to assess maximal oxygen consumption (VO2max), peak exercise capacity and ventilatory anaerobic threshold (VAT) at the time of enrollment, which was repeated at 6 and 12 months after pacemaker implantation.

After a 5-min rest period, the patients were subjected to an examination on a bicycle ergometer. During exercise a 12-lead ECG was recorded and the heart rate was continuously calculated based on R–R interval. The arterial blood pressure was measured at rest and at least once at a given resistance level. A ramp protocol was employed with continuously increasing resistance of 25 W every 2 min starting at 0 W. Subjects were exercised to fatigue or until one of the following termination criteria was met: chest pain or dizziness, potentially dangerous arrhythmias or ST-segment deviations, marked systolic hypotension or hypertension [14]. During the test, the patient breathed through a tight-fitting mask. The inhaled and the exhaled air volume and flow were measured by a connected spirometer. Additionally, the oxygen consumption (VO2) and carbon dioxide production (VCO2) were quantified. Maximal oxygen consumption (VO2max) was defined as the highest VO2 obtained during the entire test and expressed in ml/min/kg [15]. The ventilator anaerobic threshold VAT was determined as the first non-linear increase in the ventilatory equivalent for oxygen without a simultaneous increase of the ventilatory equivalent for CO2 [16].

Statistical analysis

Data were tested for normal distribution. Results of continuous variables are expressed as means ± standard error of the mean. Statistical analyses were done using the 2-tailed, unpaired Student’s t-test. Level of significance was set to p < 0.05. Categorical variables are presented as total number with comparison using chi-square statistics and Fisher exact test. If more than 2 groups were analyzed, a one-way ANOVA test was performed. Post hoc analyses were applied using Bonferroni method. Significance level was set to p < 0.05.

Results

Study population and procedural data

Primary 48 patients were included in the retrospective analysis for the 24 month long time follow-up. In addition, 60 consecutive patients were included in the current prospective 12-month short time analysis for a more detailed echocardiographic and spiroergometric evaluation (Fig. 1). The patients were divided into two groups. The high RV pacing burden group (hRVP) was defined as subjects...
with a RV pacing ≥ 40% according to the definitions in previous randomized trials [7]. In contrast, the low RV pacing burden group (lRVP) was defined as RV pacing < 40%. The two treatment groups were well balanced in regards to demographics and clinical baseline characteristics for the retrospective and prospective registry. These are shown in Table 1. In the retrospective cohort the patients in the hRVP group were significantly older compared to the IRVP subjects (58 years vs. 72 years; p < 0.05). Additionally, in the retrospective cohort notably more dual-chamber pacemakers were implanted in the IRVP patients. There were no relevant differences in gender, co-morbidities and concomitant medications in both groups.

The RV pacing burden was registered at the following routine pacemaker checkups: 4 weeks after pacemaker implantation as well as 6, 12 and 24 months after implantation. No crossover patients from the hRVP to the IRVP group during the follow-up were identified. In the retrospective analysis the average RV pacing burden was 12.3% in the IRVP group versus 75.5% in the hRVP group. In the prospective part of the registry the RV pacing burden was 9.6% in the IRVP patients vs. 78.9% in the hRVP group.

Further results are evaluated below separately for the retrospective and prospective parts of the registry.

Retrospective 24-month follow-up
In the retrospective cohort 88.2% of patients in the hRVP group received a pacemaker due to an AV-block, 5.9% pacemakers were implanted because of a symptomatic sick sinus syndrome and 5.9% of patients suffered from syncope with bundle branch block. In contrast, only 9.7% of patients in the IRVP group suffered from an AV-block, 61.3% suffered from sick sinus syndrome and 29% from syncope with bundle branch block (Table 1).

Change of echocardiographic parameters depending on the RV pacing burden (primary endpoint)
The changes in more detailed echocardiographic parameters over the course of one year depending on the RV pacing burden is shown in Fig. 3 for the prospective cohort. These echocardiographic parameters also did not change significantly in the time course of 6 and 12 months, independently of the burden of RV pacing (LVDD: IRVP: baseline: 45.4 ± 0.64 mm, 6 months: 45.5 ± 0.58 mm, 12 months: 46.4 ± 0.51 mm, hRVP: baseline: 45.6 ± 1.4 mm, 6 months: 46.5 ± 1.1 mm, 12 months: 47.2 ± 1.0 mm; LVEDD: IRVP: baseline: 32.2 ± 0.74 mm, 6 months: 32.6 ± 0.62 mm, 12 months: 32.8 ± 0.61 mm, hRVP: baseline: 31.7 ± 1.5 mm, 6 months: 32.6 ± 1.2 mm, 12 months: 32.4 ± 1.1 mm; LVEF: IRVP: baseline: 59.2 ± 1.0%, 6 months: 57.9 ± 0.93%, 12 months: 57.6 ± 0.77%; hRVP: baseline: 59.7 ± 1.6%, 6 months: 58.5 ± 1.1%, 12 months: 58.8 ± 0.9%; TAPSE: IRVP: baseline: 23.7 ± 0.71 mm, 6 months: 23.5 ± 0.76 mm, 12 months: 23.4 ± 0.57 mm; hRVP: baseline: 26.0 ± 0.85 mm, 6 months: 24.2 ± 0.76 mm, 12 months: 23.3 ± 0.58 mm; E/A-ratio: IRVP: baseline: 1.01 ± 0.05, 6 months: 1.05 ± 0.05, 12 months: 0.98 ± 0.04, hRVP: baseline: 1.1 ± 0.07, 6 months: 1.1 ± 0.06, 12 months: 1.19 ± 0.08; E/E′-ratio: IRVP: baseline: 9.3 ± 0.5, 6 months: 8.6 ± 0.44, 12 months: 8.0 ± 0.31, hRVP: baseline: 10.2 ± 1.0, 6 months: 9.5 ± 0.77, 12 months: 8.8 ± 0.59).

Prospective 6- and 12-month follow-up
In the prospective cohort all patients suffered from AV-block in the hRVP group. In the IRVP group this was the case in 25.6% of patients whereas 74.4% had sick sinus syndrome (Table 1).

Change in spiroergometric parameters depending on the RV pacing burden (secondary endpoint)
Figure 4 shows the changes in spiroergometric parameters over the course of one year depending on the RV pacing burden in Fig. 3 for the prospective cohort. These spiroergometric parameters also did not change significantly in the time course of 6 and 12 months, independently of the burden of RV pacing (peak exercise capacity: IRVP: baseline: 105 ± 7 W, 6 months: 105 ± 6 W, 12 months: 114 ± 7 W, hRVP: baseline: 114 ± 12 W, 6 months: 118 ± 14 W,
**retrospective cohort**

48 consecutive patients  
(LVEF > 50%; TAPSE > 17mm; LVEDD < 57mm)  
indication for pacemaker implantation  
20 pat. sick sinus syndrome  
18 pat. AV block  
10 pat. other indication

pacemaker implantation  
baseline TTE: LVEF, TAPSE

pacemaker follow-up 24 month

31 pat. RV pacing < 40% (IRVP)  
17 pat. RV pacing ≥ 40% (hRVP)

follow-up TTE 24 month  
LVEF; TAPSE

**prospective cohort**

60 consecutive patients  
(LVEF > 50%; TAPSE > 17mm; LVEDD < 57mm)  
indication for pacemaker implantation  
29 pat. sick sinus syndrome  
31 pat. AV block

pacemaker implantation  
baseline TTE: LVEDD, LVESD, LVEF, E/A-ratio; E/E’-ratio and TAPSE  
baseline spiroergometry: VO₂max, peak exercise capacity, VAT

pacemaker follow-up 6 and 12 month

39 pat. RV pacing < 40% (IRVP)  
21 pat. RV pacing ≥ 40% (hRVP)

follow-up TTE 6 and 12 month  
LVEDD, LVESD, LVEF, E/A-ratio; E/E’-ratio and TAPSE

follow-up spiroergometry  
6 and 12 month  
VO₂max, peak exercise capacity, VAT

*Fig. 1* (See legend on previous page.)
**Table 1** Baseline characteristics

|                      | RV-pacing | IRVP | hRVP | p value |
|----------------------|-----------|------|------|---------|
| **(Prospective)**    |           |      |      |         |
| Total population     | 39        | 21   |      |         |
| Age, year            | 71 (11.4) | 72 (12.4) | 0.6  |
| Sex, male N (%)      | 21 (53.8) | 14 (66.7) | 0.4  |
| Comorbidities        |           |      |      |         |
| Hypertension N (%)   | 34 (87.2) | 18 (85.7) | 1.0  |
| Diabetes mellitus N (%) | 22 (56.4) | 14 (66.7) | 0.58 |
| CAD N (%)            | 24 (63.2) | 15 (71.4) | 0.57 |
| A Fib N (%)          | 5 (12.8)  | 7 (33.3)  | 0.09 |
| Medications          |           |      |      |         |
| Beta blocker N (%)   | 34 (87.2) | 18 (85.7) | 1.0  |
| ACE inhibitor N (%)  | 34 (87.2) | 34 (87.2) | 1.0  |
| **Type of pacemaker**|           |      |      |         |
| Single-chamber N (%) | 2 (5.1%)  | 5 (23.8%) | 0.25 |
| Dual-chamber N (%)   | 37 (94.9)| 16 (76.2%) | 0.25 |
|                    |           |      |      |         |
| **(Retrospective)**  |           |      |      |         |
| Total population     | 31        | 17   |      |         |
| Age, year            | 58 (13.5) | 72 (6.1)  | <0.05|
| Sex, male N (%)      | 19 (61.3) | 8 (47.1)  | 0.37 |
| Comorbidities        |           |      |      |         |
| Hypertension N (%)   | 26 (83.9) | 16 (94.1) | 0.40 |
| Diabetes mellitus N (%) | 10 (32.3) | 5 (29.4)  | 1.0  |
| CAD N (%)            | 19 (10.3) | 14 (82.4) | 0.196|
| A Fib N (%)          | 1 (3.2)   | 7 (41.2)   | <0.05|
| Medications          |           |      |      |         |
| Beta blocker N (%)   | 26 (83.9) | 17 (100)   | 0.14 |
| ACE inhibitor N (%)  | 26 (83.9) | 16 (94.1) | 0.40 |
| Pacemaker indication |           |      |      |         |
| SSS N (%)            | 29 (74.4) | 10 (25.6) | 21 (100)|
| AV-block N (%)       | 10 (25.6) | 21 (100)  |      |
| Type of pacemaker    |           |      |      |         |
| Single-chamber N (%) | 34 (87.2) | 34 (87.2) | 1.0  |
| Dual-chamber N (%)   | 10 (25.6) | 21 (100)  |      |

The statistical significance level was set to p < 0.05. Therefore all p-values that reach this level were marked in bold.

**RV-pacing:** right ventricular pacing; **IRVP:** RV pacing < 40%; **hRVP:** RV pacing ≥ 40%

**CAD:** coronary artery disease; **A Fib:** atrial fibrillation; **SSS:** sick sinus syndrome; **AV-Block:** atrioventricular block; **ACE-Inhibitor:** angiotensin-converting enzyme; **Other pacemaker indications:** bundle branch block and syncope or syncope with positive electrophysiological study (HV-interval > 70 ms)

12 months: 127 ± 15 W; **VO_{2max}:** IRVP: baseline: 22.5 ± 0.8 ml/min/kg, 6 months: 22.8 ± 0.8 ml/min/kg, 12 months: 23.1 ± 0.9 ml/min/kg, **hRVP:** baseline: 21.4 ± 1.4 ml/min/kg, 6 months: 22.9 ± 1.9 ml/min/kg, 12 months: 24.4 ± 2.0 ml/min/kg; **VAI:** IRVP: baseline: 88.2 ± 6 W, 6 months: 85.8 ± 6 W, 12 months: 86.2 ± 6 W, **hRVP:** baseline: 82.0 ± 14 W, 6 months: 80.9 ± 14 W, 12 months: 85.0 ± 14 W).

**Discussion**

The present pacemaker registry represents a detailed observational study regarding the influence of RV pacing on various echocardiographic and spiroergometric parameters in patients with preserved left ventricular function over a period of 12 and 24 months of pacemaker therapy. The main findings of this pacemaker registry were as follows: in the first retrospective part of the registry no relevant worsening of the LVEF and TAPSE could be observed within 24 months either in patients with a low RV pacing burden (<40%) or in subjects with a high RV pacing burden with (>40%). In the second prospective part of the current registry more detailed echocardiographic parameters including LVEDD, LVESD, LVEF, TAPSE, E/A-ratio and E/E′-ratio were measured 6 and 12 months after pacemaker implantation in order to reveal changes in the LV geometry and diastolic function in relation to RV pacing. Similarly, in the prospective study the comparison between subjects with low (>40%) and high (<40%) right ventricular pacing burden yielded no significant differences with regard to the echocardiographic parameters. These results were also reflected in the clinical short term outcome of the current registry, which was determined by spiroergometry. Accordingly, no relevant changes of peak exercise capacity, ventilatory anaerobic threshold and maximal oxygen consumption could be recorded independently of the RV pacing burden in the short term follow-up up to 12 months.

Controversial data exist concerning the long-term effect of chronic RVA pacing on the systolic LV function of patients with preserved LVEF. On the one hand the results of the current registry are in line with different previous studies. A large cohort study of pacemaker recipients with predominantly normal LVEF was also unable to demonstrate a clinically relevant decrease in LVEF due to RV pacing even after 44 months of follow-up [2]. Moreover, the randomized prospective PREVENT-HF Study did not demonstrate significant differences in several echocardiographic parameters after 12 months between RV apical and biventricular pacing for AV block [8]. In addition, a large registry of the Mayo Clinic could not reveal any statistically significant change in mean LVEF in long-term follow-up in patients with preserved LVEF who underwent AVJ ablation and RVA pacing [3]. On the other hand, in another large registry by Bansal et al. the incidence of pacemaker-induced
cardiomyopathy, defined as decrease of ≥ 10% in LVEF caused by high burden of RV pacing was found to be 13.8% over a mean follow-up of 14.5 months [4]. In a further registry with 184 pacemaker patients as many as 22.8% of subjects developed a pacemaker-induced cardiomyopathy, with decrease in mean LVEF from 62.1 to 35.3% over a mean follow-up of 2.5 years [17]. Of note, in this study frequent RV pacing was defined as ≥ 20% RV pacing burden [17]. Thereby, the burden of right ventricular pacing and interventricular dyssynchrony were identified as the most important predictors for the development of pacemaker-induced cardiomyopathy [4]. Similarly to the current registry, in the previous randomized MOST and DAVID trials the RV pacing burden threshold for worsened clinical outcome was determined at 40%. Another study, however, also reported that pacemaker induced cardiomyopathy is not uncommon in patients receiving pacemaker for complete heart block with preserved LVEF and is strongly associated with RV pacing burden > 20% [18]. Nonetheless, there are no data to support any clearly defined limit below which RV pacing is safe and beyond which RV pacing is harmful [10].

It has been discussed that the location of the RV lead plays a role in the development of pacemaker induced cardiomyopathy. Some registries, nevertheless, have shown that non-apical RV pacing site does not offer any benefit in terms of incidence of pacemaker-induced cardiomyopathy over apical lead position [4]. Further, the Protect PACE study, which enrolled patients with complete heart block and preserved LVEF (> 50%) failed to demonstrate that RV high septal pacing was more beneficial than the standard RV apical pacing with respect to LVEF [19]. In addition, in patients with complete AV block with pacing-dependent rhythm, regardless of the pacing site, the paced QRS duration was a major determinant of the occurrence of pacemaker induced cardiomyopathy [20]. This finding is supported by the register of Khurshid et al. that showed that a paced QRS duration ≥ 150 ms was associated with the presence of pacemaker induced cardiomyopathy [17]. In the current registry all RV leads were implanted in a RV apical septal position. The QRS duration before and after pacemaker implantation was unfortunately not registered. Therefore, no conclusion can be drawn about the influence of the position of the RV lead and the paced QRS duration in
Fig. 3 (See legend on previous page.)
Another factor in the development of the disease seems to be the total duration of pacemaker therapy. In the current registry no pacemaker induced cardiomyopathy could be diagnosed during a follow-up of 6, 12 and 24 months after pacemaker implantation. Previous registries reported an occurrence of pacemaker-mediated cardiomyopathy in the first 6–12 month of pacemaker treatment [1, 21]. However, this kind of cardiomyopathy could occur more than a decade after pacemaker implantation [22]. Therefore, the follow-up period in the current registry should have been adequate to register at least the early onsets of pacemaker-induced cardiomyopathy. Yet it must be critically noted that given a longer follow-up period more patients with a pacemaker induced cardiomyopathy could have been identified.

In addition to all the above-mentioned contributing factors, baseline LVEF appears to be one of the most important predictors for the development of a pacemaker-induced cardiomyopathy in various previous studies [3, 23]. This is absolutely consistent with the current study, which could not detect pacemaker-induced worsening of echo parameters in patients with preserved LVEF.

The LVEF also appears to play a critical role in the clinical outcome of RV pacing. Thus in the DAVID trial patients with standard indications for ICD therapy and an LVEF of 40% or less, RV pacing increased the combined end point of death or hospitalization for heart failure [7]. Furthermore, the Mode selection trial (MOST) could reveal an increased risk of heart failure and atrial
fibrillation over a period of 6 years in patients with a cumulative RV pacing > 40% compared to patients with a low RV pacing burden [6]. Of note, in the MOST trial the clinical endpoints were not analysed with respect to the LV function. In addition, in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II study, RV pacing burden > 50% was associated with new onset or worsening of heart failure symptoms [24]. Due to the ongoing discussion about the adverse potential of RV stimulation in recent years, various pacemaker programming algorithms, switching from AAI(R) to DDD(R), have been developed to reduce unnecessary RV stimulation as much as possible [25]. However, it should be kept in mind, that the subsequent MVP trial (Managed Ventricular pacing vs. VVI 40 Pacing) failed to demonstrate non-inferiority of this algorithm [26]. Also a previous meta-analysis revealed that the reduction of unnecessary ventricular pacing fails to affect hard clinical outcomes such as permanent atrial fibrillation, all-cause hospitalization or all-cause mortality in patients with preserved left ventricular function [27]. In addition, it could be shown that the burden of RV pacing does not influence the quality of life in pacemaker patients [28].

Further, the incidence of atrial fibrillation as a sign of pacemaker-induced cardiomyopathy was significantly higher in patients with a high RV pacing burden compared to atrial-only pacing [29]. In the current registry the incidence of atrial fibrillation depending on RV pacing burden was not investigated. Nor were clinical endpoints such as the incidence of heart failure or atrial fibrillation chosen. However, changes in surrogate spiroergometric parameters for heart failure were explored. In accordance with the echo data no relevant changes of peak exercise capacity, ventilatory anaerobic threshold and maximal oxygen consumption could be revealed independently of the RV pacing burden in the short term follow-up of 12 months. Based on these data it could be proposed that in patients with preserved LVEF pacemaker therapy is unlikely to affect functional capacity. However, according to some literature it is not the RV pacing burden itself but the programmed AV interval which influences the exercise capacity [30]. Therefore, if a patient’s exercise capacity deteriorates under RV pacing, an echocardiographic optimisation of AV interval should be considered as primary non-invasive approach.

There are several therapeutic approaches to reduce the incidence of the pacemaker-mediated cardiomyopathy. In this context, the BLOCK-HF study suggests that patients with LVEF < 50% and AV block may benefit from biventricular pacing compared to RV pacing in terms of heart failure [31].

Similarly, in the long-term follow-up from the PACE study, HF hospitalizations were significantly increased among those receiving RV pacing compared to the CRT group [32]. Further, the 2-year results of the PACE trial showed that biventricular pacing minimizes LV dysynchrony, preserves LV function, and reduces NT-proBNP in contrast to DDD(R) pacing in patients with high-grade AV block [9]. In contrast, in the echo-CRT study CRT therapy failed to prevent death from any cause or first hospitalization for worsening heart failure in patients with LVEF < 35% and QRS duration < 130 ms [33]. Another promising therapy concept for preventing or reversal of pacemaker-induced cardiomyopathy is the HIS bundle pacing (HBP) [34, 35].

Inspired by an excellent editorial written by Dr. Israel about his “top 10 excuses” with regard to unexpected results in prospective pacemaker studies, this study has several surmountable limitations as well [36]. First, the current study subjects were not randomised into the high and low RV pacing group. Second, the study population was too small to make valid conclusions about clinical endpoints like heart failure or mortality. Furthermore, the small sample size of the current registry negatively influences the power of the results regarding the echocardiographic and spiroergometric endpoints. Additionally, the current study cannot rule out long-term negative effects of RV stimulation, as the follow-up period did not exceed 24 months. Another limitation of this registry is the missing propensity matched analysis between the pacing groups to rule out potential sampling errors, which was not reasonable due to the small sample size. Another unusual aspect of the current registry is the divided design into a retrospective and prospective part. However, the expansion of the registry to a prospective part in order to include more detailed echo- and spiroergometric parameters is very useful for supporting the retrospective data.

**Conclusions**

In summary, the current pacemaker registry regarding changes in echocardiographic and spiroergometric surrogate parameters of heart failure depending on RV pacing burden supports previous studies showing that pacemaker induced cardiomyopathy is a rare complication especially in patients with preserved LVEF in short term follow-up over 24 months. Despite this, screening for pacemaker induced cardiomyopathy should be performed particularly in the presence of new heart failure symptoms.

**Abbreviations**

AFib: Atrial fibrillation; CAD: Coronary artery disease; HBP: HIS bundle pacing; hRVp: High RV pacing burden group; lRVp: Low RV pacing burden group; LV: Left ventricular; LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; MADIT: Multicenter Automatic Defibrillator Implantation Trial; MVP: Managed Ventricular pacing; PACE: Preventing Arrhythmia with Electrical Cardioversion; RV: Right ventricular; RVp: RV pacing burden; TIs: Transmission incompetence; TFP: Tracking failure; UTR: Undetermined transmission; WRF: Widespread R綊 fusion; YS: Young鼬; YS/YP: Young鼬/Young adult;.
ventricular ejection fraction; LVEF: left ventricular end systolic diameter; RV: Right ventricular; SSS: Sinus node syndrome; TAPSE: Tricuspid annular plane systolic excursion; VAT: Ventilatory anaerobic threshold; VO2max: Maximal oxygen consumption.

Acknowledgements
We thank all staff of the cardiopulmonary function diagnostics at Dresden Heart Centre for supporting this registry.

Author contributions
MC and CW designed the work; AU, MG, SK, UR, the acquisition, analysis; KI and AF: interpretation of data; CP, MC and MD have drafted the work or substantively revised it. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This study was not supported by any grant.

Availability of data and materials (data transparency)
The data that support the findings of this study are available from the first author, AU, upon reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the institutional ethical review board. All data were collected, managed and analysed at the Heart Centre, University of Dresden (ethics votum University of Dresden: EK 28409202). Written informed consent was obtained from all individual participants included in the study.

Consent for publication
Not applicable.

Competing interests
All authors report no competing interests.

Author details
1 Technische Universität Dresden, (Campus Chemnitz), Klinikum Chemnitz, Flemmingstrasse 2, 09116 Chemnitz, Germany. 2 Technische Universität Dresden, University of Dresden, Fetscherstrasse 76, 01307 Dresden, Germany. 3 HELIOS Hospital Pirna: HELIOS Klinikum Pirna, Struppener Strasse 13, 01796 Pirna, Germany.

Received: 13 June 2021   Accepted: 15 December 2021
Published online: 31 January 2022

References
1. Merchant FM, Hoskins MH, Musat DL, Prillinger JB, Roberts GJ, Nabutovsky Y, Mittal S. Incidence and time course for developing heart failure with high-burden right ventricular pacing. Circ Cardiovasc Qual Outcomes. 2017;10(6):e003564.
2. Ebert M, Jander N, Minners J, Blum T, Doering M, Bollmann A, Hindricks G, Arentz T, Kaluschke D, Richter S. Long-term impact of right ventricular pacing on left ventricular systolic function in pacemaker recipients with preserved ejection fraction: results from a large single-center registry. J Am Heart Assoc. 2016;5(7):e003845.
3. Chen L, Hodge D, Jahangir A, Ozcan C, Trusty J, Friedman P, Rea R, Bradley D, Brady P, Hammill S, et al. Preserved left ventricular ejection fraction following atrioventricular junction ablation and pacing for atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(1):119–27.
4. Bansal R, Parakh N, Gupta A, Junqua R, Naik N, Yadav R, Sharma G, Roy A, Verma SK, Bahl VR. Incidence and predictors of pacemaker-induced cardiomyopathy with comparison between apical and non-apical right ventricular pacing sites. J Interv Card Electrophysiol. 2019;56(1):63–70.
5. Sharma AD, Rizo-Patron C, Hallstrom AP, O’Neill GP, Rothbart S, Martins JB, Roecke M, Steinberg JS, Greene HL. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm. 2005;2(8):830–4.
6. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107(23):2932–7.
7. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutakel SP, Sharma A. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288(24):3115–23.
8. Stockburger M, Gomez-Doblas JJ, Lamas G, Alzueta J, Fernandez-Lozano I, Cobo E, Wiegand U, Concha JF, Navarro X, Navarro-Lopez F, et al. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). Eur J Heart Fail. 2011;13(6):633–41.
9. Albertsen AE, Nielsen JC, Poulsen SH, Mortensen PT, Pedersen AK, Hansen PS, Jensen HK, Egeblad H. Biventricular pacing prevents left ventricular performance in patients with high-grade atrio-ventricular block: a randomized comparison with DDDR(R) pacing in S0 consecutive patients. Europace. 2008;10(3):314–20.
10. Gillson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabés JA, Boriani G, Braunischwieg F, Brignole M, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European Heart Rhythm Association (EHRA). Eur Heart J. 2021;42:3427–520.
11. Shah AM, Caggott B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015;132(5):402–14.
12. Kaul S, Tei C, Hopkins JM, Shaw PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J. 1984;107(3):526–31.
13. Naghueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokiainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321–60.
14. Duncan GE, Howley ET, Johnson BN. Applicability of VO2max criteria: discontinuous versus continuous protocols. Med Sci Sports Exerc. 1997;29(2):273–8.
15. Arena R, Humphrey R, Peberdy MA. Prognostic ability of VE/VO2 slope calculations using different exercise test time intervals in subjects with heart failure. Eur J Cardiovasc Prev Rehabil. 2003;10(6):463–8.
16. Wasserman K, Beaver WL, Whipp BJ. Gas exchange theory and the lactic acidosis (anaerobic) threshold. Circulation. 1990;81(1 Suppl):II14–30.
17. Khushid S, Liang J, Owens A, Lin D, Schaller R, Epstein AE, Mathlinski FE, Frankel DS. Longer paced QRS duration is associated with increased prevalence of right ventricular pacing-induced cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27(10):1174–9.
18. Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, Kanj M, Wazni OM, Saliba W, Varma N, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016;13(12):2272–8.
19. Kaye GC, Linker NJ, Marwick TH, Pollock L, Graham L, Pouliot E, Poloniecki J, Gammage M. Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study. Eur Heart J. 2015;36(14):856–62.
20. Kim JH, Kang KW, Chin JY, Kim TS, Park JH, Choi YJ. Major determinant of cardiac function in patients with complete atrioventricular block: a multicentre, retrospective analysis over a 15-year period in South Korea. BMJ Open. 2018;8(2):e019048.
21. Yu CM, Chan JY, Zhang Q, Omar R, Yip GW, Hussain A, Fang F, Lam KT, Chan HC, Fung JW. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med. 2009;362(22):2123–34.
22. Li DL, Yonedza ZT, Issa TZ, Shoemaker MB, Montgomery JA. Prevalence and predictors of pacing-induced cardiomyopathy in young adult patients (< 60 years) with pacemakers. J Cardiovasc Electrophysiol. 2021;32(7):1961–8.
23. Safak E, Ince H, Gkouvatsou L, Schultheiss HP, Ortak J, Caglayan E, Oener A, D’Ancona G. Pacing-induced cardiomyopathy in chronic right ventricular apical pacing: a midterm follow-up study. Eur J Med Res. 2019;24(1):23.

24. Steinberg JS, Fischer A, Wang P, Schuger C, Daubert J, McHirt S, Andrews M, Brown M, Hall WI, Zareba W, et al. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol. 2005;16(4):359–65.

25. Sweeney MO, Ellenbogen KA, Casavant D, Betzold R, Sheldon T, Tang F, Mueller M, Lingle J. Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs. J Cardiovasc Electrophysiol. 2005;16(8):811–7.

26. Sweeney MO, Ellenbogen KA, Tang AS, Whellan D, Mortensen PT, Giraldi F, Sandler DA, Sherfesee L, Sheldon T. Atrial pacing or ventricular backup-only pacing in implantable cardioverter–defibrillator patients. Heart Rhythm. 2010;7(11):1552–60.

27. Shurrab M, Healey JS, Haj-Yahia S, Koutskaia A, Boriani G, Carrizo A, Botto G, Newman D, Padeletti L, Connolly SJ, et al. Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. Europace. 2017;19(2):282–8.

28. Maurer DE, Naegeli B, Straumann E, Bertel O, Frielingsdorf J. Quality of life and exercise capacity in patients with prolonged PQ interval and dual chamber pacemakers: a randomized comparison of permanent ventricular stimulation versus intrinsic AV conduction. Europace. 2003;5(4):411–7.

29. Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pedersen AK. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol. 2003;42(4):614–23.

30. Khairy P, Talajic M, Dominguez M, Tardif JC, Juneau M, Lavoie L, Roy D, Dubuc M. Atrioventricular interval optimization and exercise tolerance. Pacing Clin Electrophysiol. 2001;24(10):1534–40.

31. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MS. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585–93.

32. Yu CM, Fang F, Luo XX, Zhang Q, Azlan H, Razali O. Long-term follow-up results of the pacing to avoid cardiac enlargement (PACE) trial. Eur J Heart Fail. 2014;16(9):1016–25.

33. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Rorer JS, Dickstein K, Ford I, Gorcsan J 3rd, Gras D, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36(S3):1983–9.

34. Vijayarajanan P, Heirweg B, Dandamudi G, Mittal S, Bhatt AG, Markantoni L, Naperkowski A, Sharma PS, Zanon F. Outcomes of His-bundle pacing upgrade after long-term right ventricular pacing and/or pacing-induced cardiomyopathy: insights into disease progression. Heart Rhythm. 2019;16(10):1554–61.

35. Zizek D, Antolic B, Mlozar AZ, Zavr-Dzananovic D, Jan M, Stublar J, Pernat A. Biventricular versus His bundle pacing after atrioventricular node ablation in heart failure patients with narrow QRS. Acta Cardiol. 2021:1–9. (Online ahead of print)

36. Israel CW. Pacing-induced heart failure: should we avoid right ventricular pacing or not? EP Europace. 2017;19(2):165–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.